Hormonal
Subcutaneous semaglutide (1.0 mg weekly) produces significantly greater weight loss and improvements in metabolic markers (BMI, waist circumference, HbA1c, fasting glucose, systolic BP) compared to other GLP-1 receptor agonists (liraglutide, exenatide, dulaglutide) in patients with type 2 diabetes.
For patients with Type 2 Diabetes seeking weight loss, subcutaneous semaglutide (1.0 mg weekly) is a more effective option than other common GLP-1 agonists like liraglutide or dulaglutide. It leads to greater reductions in body weight, BMI, and waist circumference, as well as better improvements in blood sugar (HbA1c) and blood pressure. While gastrointestinal side effects like nausea are common, they often decrease over time, and the metabolic benefits are substantial.
Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D... In direct comparisons, 1.0-mg semaglutide resulted in significantly greater weight loss than 2.0-mg exenatide... 1.2-mg liraglutide... and 1.5-mg dulaglutide.
Why this rating
Based on 5 randomized controlled trials with low risk of bias, though heterogeneity prevented meta-analysis.
Source
Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review
Brandon Stretton et al. · Internal Medicine Journal · 2023
DOI 10.1111/imj.16126
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →